Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 251

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial

Open access
You, Rui, Liu, You-Ping, Huang, Pei-Yu, Zou, Xiong, Sun, Rui, He, Yu-Xiang, Wu, Yi-Shan, Shen, Guo-Ping, Zhang, Hong-Dan, Duan, Chong-Yang, Tan, Sze Huey, Cao, Jing-Yu, Li, Ji-Bin, Xie, Yu-Long, Zhang, Yi-Nuan, Wang, Zhi-Qiang, Yang, Qi, Lin, Mei, Jiang, Rou, Zhang, Meng-Xia, Hua, Yi-Jun, Tang, Lin-Quan, Zhuang, Ai-Hua, Chen, Qiu-Yan, Guo, Ling, Mo, Hao-Yuan, Chen, Yong, Mai, Hai-Qiang, Ling, Li, Liu, Qing, Chua, Melvin Lee Kiang, Chen, Ming-Yuan·2020·JAMA Oncology

Abstract

Importance: The role of locoregional radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma (mNPC) is unclear. Objective: To investigate the efficacy and safety of locoregional radiotherapy in de novo mNPC. Design, Setting, and Participants: Patients with biopsy-proven mNPC, who demonstrated complete or partial response (RECIST v1.1) following 3 cycles of cisplatin and fluorouracil chemotherapy, were enrolled. Eligible patients were randomly assigned (1:1) to receive either chemotherapy plus radiotherapy or chemotherapy alone. Overall, 126 of 173 patients screened were eligible to the study, and randomized to chemotherapy plus radiotherapy (n = 63) or chemotherapy alone (n = 63). Median (IQR) follow-up duration was 26.7 (17.2-33.5) months. Interventions: The chemotherapy regimens were fluorouracil continuous intravenous infusion at 5 g/m2 over 120 hours and 100 mg/m2 intravenous cisplatin on day 1, administered every 3 weeks for 6 cycles. Patients assigned to the chemotherapy plus radiotherapy group received intensity-modulated radiotherapy (IMRT) after chemotherapy. Main Outcomes and Measures: The primary end point of the study was overall survival (OS). The secondary end point was progression-free survival (PFS) and safety. Results: Overall, 126 patients were enrolled (105 men [83.3%] and 21 women [16.7%]; median [IQR] age, 46 [39-52] years). The 24-month OS was 76.4% (95% CI, 64.4%-88.4%) in the chemotherapy plus radiotherapy group, compared with 54.5% (95% CI, 41.0%-68.0%) in the chemotherapy-alone group. The study met its primary end point of improved OS (stratified hazard ratio [HR], 0.42; 95% CI, 0.23-0.77; P = .004) in favor of chemotherapy plus radiotherapy. Progression-free survival was also improved in the chemotherapy plus radiotherapy group compared with the chemotherapy-alone group (stratified HR, 0.36; 95% CI, 0.23-0.57). No significant differences in acute hematological or gastrointestinal toxic effects were observed between the treatment arms. The frequency of acute grade 3 or higher dermatitis, mucositis, and xerostomia was 8.1%, 33.9%, and 6.5%, respectively, in the chemotherapy plus radiotherapy group. The frequency of late severe grade 3 or higher hearing loss and trismus was 5.2% and 3.4%, respectively, in the chemotherapy plus radiotherapy group. Conclusions and Relevance: In this randomized clinical trial, radiotherapy added to chemotherapy significantly improved OS in chemotherapy-sensitive patients with mNPC. Trial Registration: ClinicalTrials.gov Identifier: NCT02111460.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2020.1808

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 251

Metadata

Authors
You, R., Liu, Y.-P., Huang, P.-Y., Zou, X., Sun, R., He, Y.-X., Wu, Y.-S., Shen, G.-P., Zhang, H.-D., Duan, C.-Y., Tan, S. H., Cao, J.-Y., Li, J.-B., Xie, Y.-L., Zhang, Y.-N., Wang, Z.-Q., Yang, Q., Lin, M., Jiang, R., Zhang, M.-X., Hua, Y.-J., Tang, L.-Q., Zhuang, A.-H., Chen, Q.-Y., Guo, L., Mo, H.-Y., Chen, Y., Mai, H.-Q., Ling, L., Liu, Q., Chua, M. L. K., & Chen, M.-Y.
Venue
JAMA Oncology
Published
2020-09-01
Volume
6
Issue
9
Pages
1345
ISSN
2374-2437 (ISSN-L)
OpenAlex
W3045194380
Cited by
251
References
2
FWCI
25.42
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaoncol.2020.1808
The paper
You, R., Liu, Y.-P., Huang, P.-Y., Zou, X., Sun, R., He, Y.-X., Wu, Y.-S., Shen, G.-P., Zhang, H.-D., Duan, C.-Y., Tan, S. H., Cao, J.-Y., Li, J.-B., Xie, Y.-L., Zhang, Y.-N., Wang, Z.-Q., Yang, Q., Lin, M., Jiang, R., . . . Chen, M.-Y. (2020). Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2020.1808

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.